Zydus Cadila gets USFDA nod for ezetimibe tablets
New Delhi: Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to market ezetimibe tablets used to treat high cholesterol.
The company has received the final approval from the USFDA to market ezetimibe tablets USP, 10 mg, Zydus Cadila said in a BSE filing.
Ezetimibe is a drug used to reduce high cholesterol levels, the company said adding that it will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
As per IMS MAT April 2017 data, the ezetimibe tablets have an estimated sales of $2.7 billion, it added.
The group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs), the company said.
Shares of Cadila Healthcare were trading 0.72% down at Rs544.40 on BSE.
- Centre plans ‘halfway homes’ to help rehabilitate the mentally ill
- HUL: Rural growth yet to recover from demonetisation, farm crisis
- Militancy growing in Jammu and Kashmir as terrorist influx continues, warn officials
- Emmanuel Macron lays out vision of a Europe fit for globalized world
- British engineer James Dyson to build electric car by 2020